Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141 | Zendy

Maura L. Gillison | Zendy; George R. Blumenschein | Zendy; Jérôme Fayette | Zendy; J. Guigay | Zendy; A. Dimitrios Colevas | Zendy; Lisa Licitra | Zendy; Kevin J. Harrington | Zendy; Stefan Kasper | Zendy; Everett E. Vokes | Zendy; Caroline Even | Zendy; Francis P. Worden | Zendy; Nabil F. Saba | Zendy; Lara Carmen Iglesias Docampo | Zendy; Robert I. Haddad | Zendy; Tamara Rordorf | Zendy; Naomi Kiyota | Zendy; Makoto Tahara | Zendy; Vijayvel Jayaprakash | Zendy; Wei Li | Zendy; Robert L. Ferris | Zendy

Open Access

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

Author(s) -

Maura L. Gillison,

George R. Blumenschein,

Jérôme Fayette,

J. Guigay,

A. Dimitrios Colevas,

Lisa Licitra,

Kevin J. Harrington,

Stefan Kasper,

Everett E. Vokes,

Caroline Even,

Francis P. Worden,

Nabil F. Saba,

Lara Carmen Iglesias Docampo,

Robert I. Haddad,

Tamara Rordorf,

Naomi Kiyota,

Makoto Tahara,

Vijayvel Jayaprakash,

Wei Li,

Robert L. Ferris

Publication year - 2022

Publication title -

the oncologist

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.176

H-Index - 164

eISSN - 1549-490X

pISSN - 1083-7159

DOI - 10.1093/oncolo/oyab036

Subject(s) - nivolumab , medicine , hazard ratio , oncology , head and neck cancer , adjuvant , subgroup analysis , confidence interval , randomized controlled trial , cancer , immunotherapy

In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator’s choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) post-platinum therapy. Nivolumab versus IC as first-line treatment also improved OS among patients with R/M SCCHN who progressed on platinum therapy for locally advanced disease in the adjuvant or primary setting at 1-year follow-up. In the present long-term follow-up analysis of patients receiving first-line treatment, OS benefit with nivolumab (n = 50) versus IC (n = 26) was maintained (median: 7.7 months versus 3.3 months; hazard ratio: 0.56; 95% confidence interval, 0.34-0.94) at 2 years. No new safety signals were identified. In summary, this long-term 2-year analysis of CheckMate 141 supports the use of nivolumab as a first-line treatment for patients with platinum-refractory R/M SCCHN.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research